Hemofilia: validação da versão brasileira do VERITAS-Pro para avaliação da adesão à profilaxia e custo-análise do tratamento
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
Prophylaxis is the therapeutic regimen of choice for individuals with severe hemophilia.
However, its effectiveness may be limited by the patient's low adherence,
compromising the results, despite the high costs of treatment. The objectives of this
study were: 1) to validate the Brazilian version of the VERITAS-Pro questionnaire for
assessing adherence to prophylaxis and 2) to assess the direct medical costs of
hemophilia treatment from the perspective of the Unified Health System, underscoring
the increase in public spending after the incorporation of therapeutic modalities such
as prophylaxis, immunotolerance, and the use of recombinant products. The study was
conducted at the Juiz de Fora Regional Blood Center between 2015 and 2016. For
validation, the US version of the VERITAS-Pro was translated and adapted to Brazilian
Portuguese and administered to 32 persons responsible for the prophylaxis of
hemophilia patients, and to 5 observers of the treatment conducted. Measures for
validation included results obtained from visual analogue scales of adherence,
medications dispensed by the blood center pharmacy, and percentage of
recommended doses administered, obtained from patient infusion diaries. The internal
consistency was very good for VERITAS-Pro's overall score, excellent for the
subscales "remember", "skip", and "communicate", good for the subscale "dose" and
acceptable for "time" and "plan". Twelve participants answered the questionnaire on
more than one occasion, to evaluate reproducibility. The intraclass correlation
coefficient was excellent. Regarding convergent validity, the VERITAS-Pro scores
were moderately correlated with the visual scale and with the infusion diaries, but
showed poor correlation with pharmacy dispensing records. Thus, the Brazilian version
of the VERITAS-Pro proved to be a valid and reliable instrument that can facilitate
understanding of specific factors related to adherence and permit more targeted
interventions. For the cost analysis study, sociodemographic, clinical, and therapeutic
data were collected retrospectively from the medical records of 98 hemophilia patients
treated between January 2011 and December 2015. Consultations, examinations,
hospitalizations, and medications were assigned costs according to the Management
System for the Table of Procedures, Medications, and Orthoses, Prostheses, and
Materials, and the Medications Price List of the Brazilian Health Regulatory Agency.
From the total number of patients, 43.3% had severe hemophilia and 32.7% had
moderate hemophilia; 36 adhered to the prophylaxis, with 29 in the tertiary form; two
presented positive inhibitor screening; and one received immunotolerance. The
number of consultations and the consumption of blood products were higher in the
group with severe hemophilia. Hospitalizations were rare. Arthropathy was not staged
and there were no orthopedic surgeries. Direct costs increased 286.8% over the period
evaluated. The mean annual cost per patient was 57,416.43 Brazilian Reais (2,962.10
BR in mild hemophilia - 89,467.77 BR in severe cases), with no significant difference
between hemophilia A and B. Blood products corresponded to 99.46% of the total cost.
The implementation of prophylaxis has considerably increased the direct costs of
treating hemophilia. The inclusion of patients with unmeasured arthropathy in
prophylactic regimens makes it impossible to assess the cost-effectiveness of this
approach, making it difficult to define priorities given the scarcity of financial resources.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
